Literature DB >> 6153391

Interaction of somatomedin-C with an antibody directed against the synthetic C-peptide region of insulin-like growth factor-I.

R L Hintz, F Liu, L B Marshall, D Chang.   

Abstract

Insulin-like growth factor-I is a human plasma peptide with strong structural homology to human prosinsulin. This peptide has been classified as a somatomedin on the basis of its biological actions and growth hormone dependence. We have generated an antibody to the synthetic 12 amino acid C-peptide region of insulin-like growth factor-I and used it to compare three somatomedin preparations to insulin-like growth factor-I. We also compared these somatomedin preparations to insulin-like growth factor-I using the standard SM-C RIA. We conclude that insulin-like growth factor-I and somatomedin-C behave identically in these two RIA's and are very similar if not identical molecules.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6153391     DOI: 10.1210/jcem-50-2-405

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  Minireview: Were the IGF Signaling Inhibitors All Bad?

Authors:  Heather Beckwith; Douglas Yee
Journal:  Mol Endocrinol       Date:  2015-09-14

2.  Insulin-like growth factor characteristics of an acidic non-suppressible insulin-like activity.

Authors:  A C Herington; A D Kuffer
Journal:  Biochem J       Date:  1984-10-01       Impact factor: 3.857

3.  Total synthesis of insulin-like growth factor I (somatomedin C).

Authors:  C H Li; D Yamashiro; D Gospodarowicz; S L Kaplan; G Van Vliet
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

4.  Somatomedin receptor of human placenta: solubilization, photolabeling, partial purification, and comparison with insulin receptor.

Authors:  B Bhaumick; R M Bala; M D Hollenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

5.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; H Walter; E R Froesch
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.